It is a long established fact that a reader of a page when looking at its layout.

    ALyS™505N & ALyS™705

    Serum free medium for the activation and expansion of Human Lymphocyte

    Product Basics

    ALyS™505N is a serum-free and xeno-free medium used for the expansion and activation of human lymphocytes. It is available in four different IL-2 concentrations, suitable for activating or expanding T cells from human lymphocytes. Higher concentrations of IL-2 activate T cells, while lower concentrations are utilized for expansion. Gas-permeable culture bags are available for IL-2 free and 175 uL/mL mediums. Furthermore, higher cell proliferation can be achieved using a small amount of Artificial Serum. ALyS™705 is a serum-free and animal-free medium, chemically defined, used for the expansion and activation of human lymphocytes. Unlike ALyS™505N, ALyS™705 achieves an animal-free culture environment by utilizing a high molecular polymer instead of albumin, which in turn reduces the shear stress generated between cells. When supplemented with Artificial Serum., ALyS™705 has shown higher proliferation rates than ALyS™505N.

    Key Features

    Technical Information

    High Cell Proliferation

    Anti-CD3 activated lymphocytes from peripheral blood (T cells) are cultured for 5 days to measure cell proliferation.

    Proliferation of anti-CD3 activated lymphocytes

    Fig. 1
    ALyS™505N (blue) can maintain high proliferation of anti-CD3 activated lymphocytes as effectively as Medium A (orange), and more efficiently than RPMI-1640 with 10% serum (green)

    Comparison of ALyS™505N and ALyS™705

    Anti-CD3 activated lymphocytes (T-cells) cultured in ALyS™705 and ALyS™505N showed similar cell proliferation.

    Fig. 2
    Anti-CD3 activated lymphocytes (T-cells) cultured in ALyS™705 demonstrated similar proliferation rates to those cultured in ALyS™505N. The addition of 1% human serum boosted cell proliferation in both mediums. With 1% human serum supplementation, ALyS™705 showed higher proliferation than ALyS™505N.

    Both media were supplemented with IL-2 at 700IU/mL on day 0. The concentration of IL-2 was reduced to 175IU/mL when medium was added on days 2, 3, and 4. There was no medium refreshment on days 5 and 6


    Scroll to right

    1020P10/1020C10ALyS505N-0IL-2 free1LBottle/Culture Bag4°C
    10217P10/10217C10ALyS505N-175IL-2 concentration 175lU/mL (Expansion)1LBottle/Culture Bag4°C
    1027P10ALyS505N-7IL-2 concentration 700lU/mL
    10210P10ALyS505N-10IL-2 concentration 1,000lU/mL (Activation)1LBottle4°C
    120P10ALyS705IL-2 free1LBottle4°C


    • Manufactured by: Cell Science and Technology Institute


    ALyS™505N & ALyS™705

    ALyS505N-0/IL-2 Free
    • SKU: 1020P10
    • Size: 1L (Bottle)
    • Price: $110.00$100.00
    • SKU: 1020C10
    • Size: 1L (Culture Bag)
    • Price: Contact us
    ALyS505N-175/IL-2 175IU/ml
    • SKU: 10217P10
    • Size: 1L (Bottle)
    • Price: $130.00$117.00
    • SKU: 10217C10
    • Size: 1L (Culture Bag)
    • Price: Contact us
    ALyS505N-7/IL-2 700IU/ml
    • SKU: 1027P10
    • Size: 1L (Bottle)
    • Price: $210.00$190.00
    ALyS505N-10/IL-2 1000IU/ml
    • SKU: 10210P10
    • Size: 1L (Bottle)
    • Price: $315.00$285.00
    • SKU: 120P10
    • Size: 1L (Bottle)
    • Price: $270.00$243.00



    1. Li, W. et al. Effect of IL-18 on Expansion of γδ T Cells Stimulated by Zoledronate and IL-2. Journal of Immunotherapy 33, 287–296 (2010). DOI: 10.1097/CJI.0b013e3181c80ffa
    2. Koyama, I. et al. A Clinical Trial With Adoptive Transfer of Ex Vivo-induced, Donor-specific Immune-regulatory Cells in Kidney Transplantation—A Second Report. Transplantation 104, (2020). DOI: 10.1097/TP.0000000000003149
    3. Kimura, H., Matsui, Y., Ishikawa, A., Nakajima, T. & Iizasa, T. Randomized controlled phase III trial of adjuvant chemoimmunotherapy with activated cytotoxic T cells and dendritic cells from regional lymph nodes of patients with lung cancer. Cancer Immunology, Immunotherapy 67, 1231–1238 (2018) DOI: 10.1007/s00262-018-2180-6
    4. Futami, M. et al. The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells. PLOS ONE 15, e0231896 (2020) DOI: 10.1371/journal.pone.0231896


    1. 1.Tomida, A. et al. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. Cancer Sci 112, 4026–4036 (2021) DOI: 10.1111/cas.15074.
    2. Mie, K., Shimada, T., Akiyoshi, H., Hayashi, A. & Ohashi, F. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection. Veterinary Immunology and Immunopathology 177, 58–63 (2016) DOI: 10.1016/j.vetimm.2016.06.007.

    Click here for more references!